Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

1 Sept 2002

Abstract excerpt

In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12176881
DOI: 10.1182/blood-2002-03-0777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CMLPMID 12176881Read ↗

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapySemantic proximity Read ↗

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapySemantic proximity Read ↗

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.Semantic proximity Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.Semantic proximity Read ↗

Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with ImatinibSemantic proximity Read ↗

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.Semantic proximity Read ↗

New Insights from Studies of Clonal Hematopoiesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.